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Abstract 
This review discusses the disposition of the anionic surfactant, sodium dodecyl sulfate (SDS; i.e., sodium 
lauryl sulfate), to solubilize sparingly-soluble drugs above the surfactant critical micelle concentration 
(CMC), as quantitated by the solubilization capacity (k). A compilation of 101 published SDS k values of 
mostly poorly-soluble drug molecules was used to develop a prediction model as a function of the drug’s 
intrinsic solubility, S0, and its calculated H-bond acceptor/donor potential. In almost all cases, the 
surfactant was found to solubilize the neutral form of the drug. Using the mass action model, the k values 
were converted to drug-micelle stoichiometric binding constants, Kn, corresponding to drug-micelle 
equilibria in drug-saturated solutions. An in-depth case study (data from published sources) considered the 
micellization reactions as a function of pH of a weak base, B, (pKa 3.58, S0 52 μg/mL), where at pH 1 the 
BH.SDS salt was predicted to precipitate both below and above the CMC. At low SDS concentrations, two 
drug salts were predicted to co-precipitate: BH.Cl and BH.SDS. Solubility products of both were determined 
from the analysis of the reported solubility-surfactant data. Above the CMC, in a rare example, the charged 
form of the drug (BH
+
) appeared to be strongly solubilized by the surfactant. The constant for that reaction 
was also determined. At pH 7, the reactions were simpler, as only the neutral form of the drug was 
solubilized, to a significantly lesser extent than at pH 1. Case studies also featured examples of 
solubilization of solids in the form of cocrystals. For many cocrystal systems studied in aqueous solution, 
the anticipated supersaturated state is not long-lasting, as the drug component precipitates to a 
thermodynamically stable form, thus lowering the amount of the active ingredient available for intestinal 
absorption. Use of surfactant can prevent this. A recently-described method for predicting the solubility 
product of cocrystals (coupled with predicted k values described here) allowed for simulations of solubility-
pH speciation profiles of cocrystal systems in the presence of SDS. Well in advance of any actual 
measurements, these simulations can be used to probe conditions favorable to the design of cocrystal 
experiments where SDS stabilizes cocrystal suspensions against drug precipitation over a predicted range of 
pH values.  
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Introduction 
This review focuses on the pharmaceutical uses of sodium dodecyl sulfate (SDS; i.e., sodium lauryl 
sulfate) to solubilize sparingly-soluble drugs by micellization. The mass action framework is used to 
describe drug-surfactant equilibria in drug-saturated suspensions as a function of pH. Examples applied to 
solids in cocrystal (CC) form are considered as part of a continuing interest in developing equilibrium 
simulation methods to identify optimal experimental conditions for cocrystal solubility-pH measurements. 
For orally administered drugs which are poorly soluble in water, a number of formulation strategies can 
be used to improve their rate and extent of absorption [1]. For solid dosage forms, recent approaches have 
included the use of CC formulations [2-5]. Cocrystal suspensions can be stabilized using surfactants [6-9]. 
For liquid dosage forms (e.g., soft gel capsules), surfactants are used to solubilize the active pharmaceutical 
ingredient (API) [10-12].  
In standard dissolution measurements of poorly-soluble solids, some compounds initially show an 
enhanced release of the API, forming a supersaturated solution, which after a while results in the 
precipitation of the crystalline API (“spring and parachute” S&P effect). Cocrystals generally show such a 
tendency. A cocrystal is a composite of an uncharged API and an uncharged water-soluble “coformer” 
molecule (e.g., saccharin, nicotinamide, 4-aminobenzoic acid, etc.). As the API in the CC is released into an 
aqueous medium, a supersaturated solution is expected to form, with the maximum theoretical drug 
concentration called “cocrystal solubility,” SCC [5-9, 13, 14]. If sustained for a few hours, this enhanced 
concentration of the API can lead to increased oral absorption [15]. Compared to amorphous solids, which 
also form supersaturated solutions, CCs, being crystalline, are likely to have better long-term solid-state 
thermal, hygroscopic, and polymorphic stability [1-3].  
The enhanced concentration of the API in CCs depends on the analytical concentrations of the two 
underlying components and on solution pH (in the case of ionizable components). Enhancement is not 
always sought: some cocrystals (e.g., slow release formulations) are designed to produce a supersaturated 
solution with an initially decreased release of a water-soluble API (“dive and surface” D&S effect) [5,16,17].  
However, the supersaturated state is not long-lasting for many CC systems studied in aqueous solution, 
given that the API (or coformer, as in the case of D&S) precipitates to a thermodynamically stable form, 
thus lowering (S&P) or raising (D&S) the concentration of the drug in solution. A way to overcome this 
API/coformer precipitation involves the use of surfactants [6-9]. 
A measure of the ability of the surfactant to solubilize a drug is referred to as solubilization capacity, 
often denoted by the symbol, k. It is defined as the number of moles of drug bound to the surfactant per 
mole of surfactant. As part of this study, 101 published SDS k values of mostly poorly-soluble drug 
molecules were gathered (Table 1). From these, a simple k prediction model was constructed, as a 
function of the API intrinsic solubility and hydrogen bond acceptor/donor potential.  
Coupled with the in silico prediction of the k values, advantage was taken of the prediction of the 
solubility product, Ksp, of cocrystals [17], to simulate aqueous solution speciation as a function of pH, using 
a recently-described computational approach [16]. These simulation calculations can be used to probe 
conditions favorable to the design of cocrystal experiments where SDS is used to stabilize CC suspensions 
against precipitation of the API. Predictions can be extended to CCs whose solution thermodynamics had 
not been studied. Even drugs not known to form CCs can be tested against a series of coformer candidates. 
Examples are presented in the study to illustrate some of the possible uses of Ksp and k values. 
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Background – Drug Solubilization by Surfactants 
Physicochemical Properties of Common Surfactants 
Surfactants are surface-active molecules which contain a hydrophobic region and a hydrophilic head 
group. Such amphiphilic molecules dissolve in aqueous solution in ways that minimize contact between 
water and hydrophobic parts of the surfactant. This lowers the free energy of solvation. At low 
concentrations these molecules tend to accumulate at the boundaries between two phases, such as the 
air-water interface, where the hydrophobic groups position on the airside. Solid-liquid interfaces may also 
be sites of adsorption (e.g., vessel walls, filter barriers, undissolved drug solids, etc.). Such available 
interfacial sites reach saturation as the surfactant concentration is increased up to the “critical micelle 
concentration” (CMC). Above the CMC, unattached surfactant monomers begin to self-associate to form 
spheroidal aggregates (“micelles”) in the bulk aqueous solution, with hydrophobic portions of the 
surfactant positioning in the core of the micelle and hydrophilic parts forming a shell around the micelle 
body. Micelles may consist of 50-100 or more surfactant molecules. The CMC is detected as the point 
corresponding to the maximum change in the gradient of a particular property (e.g., surface tension, 
conductivity, osmotic pressure, drug-micelle binding, surfactant monomer and counterion concentrations, 
etc.) vs. total surfactant concentration. On further increases in concentration above the CMC, the 
monomer concentration more or less plateaus while the micelle aggregates continue to increase in 
number but generally not in size. These micelle bodies are capable of encapsulating drug molecules. 
Poorly-soluble apolar drugs are drawn into the core of the micelle. Charged or polar amphiphilic drugs can 
position nearer the water-micelle surface.  
Sodium Dodecyl Sulfate (SDS)  
 Sodium dodecyl sulfate (SDS) is a common anionic surfactant. It is an ester of sulfuric acid, comprising a 
single aliphatic C12 chain (structure in Fig. 1a). Since the pKa is near zero, the SDS monomer is practically 
fully ionized in water. The surfactant is generally introduced into the aqueous solution as the sodium salt. 
Many of the physicochemical properties of SDS are well characterized [11, 12, 18-20]. It is considered to be 
a safe excipient in tablet or capsule formulations. In water, SDS forms nearly monodispersed micelles with 
the approximate aggregation number, Nagg = 62. At 25 °C the CMC is 8.3 mM in water (value varies 
somewhat, depending on the determination method [18, 19]). Solubilization of drugs can alter the CMC 
[12]. The negative charge of the 62-SDS micelle is approximately 80 % neutralized by about 50 sodium 
counterions, electrostatically held in the Stern layer comprising the outer shell of the spherical micelle [11]. 
Above the CMC, the solutions consist of SDS- monomers and mainly SDS62Na50
12- aggregates.  
Effective Charge on SDS Micelles 
The degree of counterion dissociation in Qm-charged SDS micelles, α = (Nagg - Qm)/Nagg, is (i) not expected 
to be greatly affected by moderate temperature changes, (ii) not affected by solubilization of small organic 
solutes, (iii) only slightly dependent on the SDS concentration, and (iv) strongly affected by the type and 
concentration of counterion [12]. Increasing ionic strength is expected to lower α (i.e., making the micelles 
less charged). In the computations here, the approximation is made that α and Nagg are constants (i.e., 
micelles are assumed to be SDS62Na50
12-).  
Mass Action Equilibrium Model for Sodium Dodecyl Sulfate (SDS)  
In the mass action treatment of the micelle formation, sodium ions, monomers, and micelles are in 
equilibrium, according to the cumulative expression below (assuming the above metrics).  






     SDS62Na50
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Figure 1 shows the simulation results based on Eq. (1), where the species in solution were calculated, as 
a function of added total surfactant concentration, using the program pDISOL-X (cf., below). 
Figure 1. Simulation of formation of SDS micelles. Sodium dodecyl sulfate added to (a) distilled water, 
(b) 0.15 M NaCl solution, and (c) pH 7 solution of 50 mM phosphate. Ionic strength and pH change as 
concentration of surfactant is increased (d). See text. 
In frame (a), simulation with aggregation constant log KSDS = 230.6 results in CMC = 8.30 mM. The KSDS 
constant was systematically varied in the calculations until the target CMC was obtained. As the surfactant 
concentration is increased in the simulation, SDS- and Na+ ions are released in equal concentrations, until 
the CMC value is reached. With further increases in surfactant concentration, the [SDS-] and [Na+] 
concentrations become unequal: that of the monomer decreases, as that of the counterion increases, due 
to the 62:50 stoichiometry of the micelles formed. The ionic strength changes over a broad range, 
increasing from 1 to 130 mM as the surfactant concentration is taken from 1 to 104 mM, which has an 
impact on the KSDS binding constant and the pH of the solution (since electrode calibration parameters 
depend on ionic strength; cf., Fig. 1d). 
In frame (b), the surfactant is added to a 0.15 M NaCl solution. Using the same KSDS constant, the CMC is 
predicted to decrease from 8.30 to 1.01 mM. The ionic strength increases over a narrow range, 151-225 
mM, as the surfactant increases in concentration from 1 to 60 mM. In the background of higher ionic 
strength, the [SDS- ] concentration remains relatively constant at 1.01 mM (the CMC value), as the 
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surfactant concentration is increased above the CMC. The [Na
+
] concentration (off-scale) remains nearly 
constant, at 150-162 mM. 
In frame (c), the surfactant is added to a 50 mM solution of phosphate buffer at pH 7. Using the same 
KSDS in the calculation, CMC = 1.78 mM. The ionic strength, which is intermediate between that of the 
above two cases (cf., Fig. 1d), clearly affects the CMC. A linear regression of the above three values of 
log CMC vs. ionic strength (ICMC, evaluated at the CMC) produces: log CMC = -3.56 - 0.73 log ICMC.  
A similar relationship, experimentally-determined by Fuguet et al. [18], is log CMC = - 3.23 - 0.49 log Ci, 
where Ci is the added counterion concentration (about 1.5 times the phosphate concentration). Fuguet 
et al. used three different methods to measure CMC. In distilled water, the measured CMC = 8.08 ± 
0.12mM; in 50 mM phosphate buffer (pH 7) CMC = 1.99 ± 0.02 mM [18]. These measured values are 
remarkably similar to those derived by purely in silico mass action simulations with the aggregation 
constant log KSDS = 230.6. The mass action model could be used to try to predict many of the factors that 
make CMC value different from that found in water, such as type and amount of electrolytes, ionic 
strength, buffer pH, temperature, and added drugs. Some examples of this will be explored below.  
In the simulations, it was found that pH could be used to indicate CMC, as shown in Figure 1d for the 
pure water case (dash-dot curve). The figure also indicates that the ionic strength increases nearly linearly 
with total surfactant added. The pDISOL-X calculation adjusts both equilibrium constants and pH electrode 
calibration parameters for changes in ionic strength. 
Molar Solubilization Capacity (k) and the Drug-Micelle Binding Constant, Kn 
The solubilization capacity (k) of a sparingly-soluble drug can be simply measured. The observed total 
solubility of the drug is plotted against the total added surfactant concentration. For [SDS]tot > CMC, the 
curve is usually linear: the slope in this region is the k value.  
 As a simplified example of the mass action methodology, consider the following chemical equilibria 
involving SDS and a basic drug, B, which has a single pKa, well below 7. Consider also that enough 
surfactant is added to water that [SDS]tot > CMC. The total micelle concentration, [mic]tot = ([SDS]tot – 
CMC)/Nagg.  
BH+                B + H+       Ka = [B][H
+] / [BH+]  (2) 
nB + mic12-    Bnmic
12-        Kn = [Bnmic
12- ] / [B] n[mic12- ]  (3) 
B(s)                         B     S0 = [B] (4) 
Kn is the drug-micelle binding constant, where n refers to the number of drug molecules bound to a 
micelle, and S0 Is the intrinsic solubility of the drug (cf., Glossary).  
If the concentration of the drug is kept below its intrinsic solubility, then Eq. (4) need not be considered. 
In such a homogeneous micellar solution, the three independent reactants are B, mic12-, and H+. The 
corresponding mass balance equations may be stated as: 
[B]tot     = [B] + [BH
+] + n[Bnmic
12- ]  (5) 
[mic]tot = [mic
12-] + [Bnmic
12- ] (6) 
[H]tot        = [H
+] – Kw / [H
+] + [BH+] . (7) 
Kw is the ionization constant of water. Eq. (7) is the hydrogen excess, which can be negative in alkaline 
solutions. On substituting the equilibrium quotients from Eqs. (2) and (3) into the mass balance equations, 
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] roots of the above equations, as well as the Kn constant, are solved using 
standard mathematical techniques [16, 17]. Kw and Ka are generally provided as fixed parameters in the 
calculation.  
If the drug precipitates in the micellar medium, then the calculation needs to incorporate Eq. (4), as 
described in detail elsewhere [16]. In the aqueous-micellar-solid medium Eq. (8) defines the total solubility 
as a function of pH and the extent of drug-micelle binding, with [B] = S0. 
Stot     = S0 (1 + 10
 –pH + pKa ) + nKn S0
n [mic12- ] 
          = S0 (1 + 10
 –pH + pKa ) + nKn S0
n /(1 + Kn S0
n) [mic]tot        
          = S0 (1 + 10
 –pH + pKa ) + nKn S0
n /(1 + Kn S0
n) { [SDS]tot – CMC }/Nagg  . (11) 
For[SDS]tot > CMC, the first derivative dStot /d[SDS]tot of the above equation defines k.  
k = n Kn S0
n / { (1 + Kn S0
n) Nagg }  
         = n fbm / Nagg  
   = Nd /Nagg  (12) 
The bound-micelle fraction, fbm = [Bnmic
12-
]/[mic]tot = Kn S0
n
 /(1 + Kn S0
n
), which can take on values 0-1. 
From this, the average number of bound drugs per micelle is Nd = n fbm. Eq. (12) indicates that k is a 
function of both the intrinsic solubility, S0, and the drug-micelle binding constant, Kn. If both k and S0 are 
known, or can be in silico estimated, then one can calculate from Eq. (12) the drug-micelle binding constant 
as: 
log Kn = log k - n log S0 + log Nagg - log (n – k Nagg) . (13) 
A single value of n implies a perfectly monodisperse distribution of micelle size. A narrow range of n 
values is more likely to reflect the actual equilibrium process, but the calculation model considered here 
assumed a single value. If the total solubility, Eq. (11), is the only dependent variable in the design equation 
to determine Kn by regression analysis, then any practical value of n > k Nagg would satisfy the fitting 
process. In the discussion here, n is taken to be k Nagg rounded up to the next integral value (using the 
modulo operator), i.e., 
 n = 1 + k Nagg – mod(k Nagg, 1)  .  (14) 
Note that Eq. (13) is only valid for solubilization of uncharged drugs (e.g., Eq. 3), where the only 
precipitate in the suspension is the nonionized drug. A different explicit equation can be derived to take 
into account charged-drug precipitation and SDS solubilization of charged drug (not done here). 
Equilibrium Model and the Computer Program  
The general computer program pDISOL-X (in-ADME Research) was used to solve mass balance 
expressions, such as Eqs. (8)-(10), for all of the reactant concentrations in both aqueous and the aqueous-
micellar-solid media. The program can analyze single-API solubility data [21-25] or cocrystal dual-
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concentration eutectic data, as a function of pH [16, 17]. Salt solubility products (including drug-SDS salt 
formation), complexation reactions (e.g., drug-micelle binding), and aggregation formations (drug or 
surfactant) can be considered. Algorithms for temperature [26] and automatic ionic strength [27] 
compensations have been incorporated. During calculation, the equilibrium constants are adjusted for 
activity effects, based on the Stokes-Robinson hydration theory [21]. The overall generalized approach 
allows for quick testing of many possible equilibrium models. 
 The details of how the solubility products are determined by regression analysis of eutectic data and 
how simulation calculations are performed using the Ksp and other equilibrium constants are not presented 
here, since that procedure already has been described in substantial depth elsewhere [16, 17]. Briefly, the 
equilibrium analysis does not depend on explicitly-derived extensions of the Henderson-Hasselbalch 
solubility equations, such as Eq. (11). The computational algorithm derives its own implicit equations 
internally in the context of the mass action model, given a set of equilibria (entered as text arrays, with 
hash tags denoting solid phase: e.g., Eqs. (2)-(4) with n=2, “B+H=BH”, “2B+mic=B2mic”, and “B=B#”) and 
the corresponding estimated equilibrium constants. The text array of equilibria is automatically parsed to 
construct the appropriate mass balance expressions in terms of reactant concentrations and equilibrium 
constants. The weighted nonlinear least-squares calculation considers the contribution from multiple 
substances – not only the API, micelle, and coformer, but also all of the reactants in solution, including 
buffers and background salts used to control the ionic strength. Currently, up to three solid phases may be 
addressed in the same calculation (provided they do not violate the Gibbs’ Phase Rule constraint, for which 
the computer program tests). In cocrystal applications, the procedure treats the measured total aqueous 
API and coformer equilibrium concentrations, [API]tot and [cof]tot, as dependent variables (cf., Appendix). 
The surfactant concentration, reactant weights, reagent volumes, and pH are treated as independent 
variables, whereas the equilibrium constants are the potentially refinable parameters.  
Data Sources 
Molar Solubilization Capacity, k  
The 101 k values used in this study were gathered from published sources [28-53], and are listed in 
Table 1. In most of the studies, multi-point aqueous-micellar-solid solubility-SDS data were displayed solely 
in plots. These plots were digitized here using WebPlotDigitizer v.3.5 
(https://automeris.io/WebPlotDigitizer/), from which the k values were re-determined, not only to 
corroborate the published k values, but also to determine the extent of nonlinearity in the [SDS] > CMC 
data. In several cases with high SDS concentrations, the slopes slightly decreased with increasing surfactant 
concentration. The re-calculated k values were equated to the slopes evaluated at the CMC. Not all values 
could be re-calculated. For example, the calculated k values of iminophenazines (including clofazimine) 
studied by Fahelelbom et al. [30] were taken directly from a plot; details of their determination were not 
reported in the publication. In just one instance, the k values were calculated from aqueous micellar 
systems (without drug precipitate): Garrone et al. [31] reported SDS-water partition coefficients, PSDS-water, 
for a series of benzoic acid derivatives, determined from shifts in the pKa values as a function of the SDS 
added. Calculated k = PSDS-water∙S0∙Vm /(1 - [SDS]tot∙Vm) [12], where the partial molar volume of SDS, Vm, was 
taken to be 0.26 M-1 [31].  
Intrinsic Solubility S0 Constants 
Drug intrinsic solubility values (S0) were taken from the literature, averaged where replicate sources 
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were available [17, 55, 56]. Most of the reported values (e.g., in the Handbook of Aqueous Solubility Data 
[54]) have been published as concentrations (Sw) in saturated aqueous solutions of the drug, added in the 
neutral form to unbuffered water. Table 1 lists the log S0, adjusted for the assay temperature [26].  
Ionization Constants (pKa) 
The pKa values used here (Table 1) were taken from the Wiki-pKa database: http://www.in-
adme.com/wiki_pka.php/. Literature pKa values are often reported at 25 °C and 0.15 M ionic strength. 
When the assay temperature or ionic strength were different from literature conditions, pKa values were 
adjusted to match the experimental conditions, using Stokes-Robinson hydration theory [21] for ionic 
strength [16, 27] and an empirical method for temperature [57] effects. 
Examples of Published Solubility-SDS Data 
Figures 2-7 illustrate drug multi-point solubility as a function of SDS concentration, with molecules 
grouped according to acid-base characteristics. In the figures, frames contain the structure of the molecule 
considered, and indicate assay temperature, solution makeup (distilled water, or buffer type and pH, or 
whether background salt had been added), equilibration times, pKa (acids underlined), log S0, and log Poct 
constants. Each curve comprises a horizontal region ([SDS] < CMC) and a region of increasing solubility 
([SDS] > CMC). The points in the latter region were selected for linear/curvilinear regression. The solid red 
curves are the connections of two curves: the regression-fitted curve and the horizontal lines where 
solubility is not appreciably affected by SDS. At the intersection of these curves (indicated by arrows) are 
concentrations which may be taken as the CMC values. The slopes of the curves in the [SDS] > CMC region 
were taken to be the k values (Table 1) and are indicated in units of moldrug/molSDS. In cases the curves 
were nonlinear, a parabolic fit was used, and the indicated slopes were evaluated at [SDS] = CMC.  
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(base) t(`C) k (calc) 
b k (obs) c ± SD N d log Kn 




S0  ±SD N  Σα2
H Σβ2
H π2 R2 Vx Comments Ref 
Artemisinin N 
  





4.52 37 0.017 0.0056 0.0002 9 5.3 1 0.35 0.35 4.54 -5.53 0.41 2 1.14 3.90 5.10 3.54 5.59 
 
[29]  
B3640 (iminophenazine) B 
 






5 3.58 -7.04 
  
0.32 1.71 2.61 3.85 3.87 
 
[30]  
B3770 (iminophenazine) B 
 






5 4.78 -8.35 
  
0.19 1.74 2.64 3.86 4.15 
 
[30]  
B3785 (iminophenazine) B 
 






8 4.39 -7.94 
  
0.19 1.73 2.64 3.86 4.01 
 
[30]  
B628 (iminophenazine) B 
 






3 3.31 -6.97 
  
0.19 1.23 2.39 3.6 3.03 
 
[30]  
B826 (iminophenazine) B 
 






7 4.50 -8.21 
  
0.19 1.76 2.55 3.65 4.12 
 
[30]  
Benzoic Acid A 3.96 
 
35 1.038 0.769 0.0473 6 71 48 0.99 47.7 1.87 -1.44 0.04 13 0.57 0.44 1.08 0.75 0.93 
 
[31] 
Benzoic Acid,3-Cl- A 3.82 
 
35 0.359 0.266 0.0258 6 43 17 0.97 16.5 2.70 -2.43 0.20 1 0.64 0.44 1.16 0.90 1.05 
 
[31] 
Benzoic Acid,3-F- A 3.86 
 
35 0.620 0.408 0.0234 6 50 26 0.97 25.3 2.15 -1.86 0.20 1 0.64 0.45 1.04 0.67 0.95 
 
[31] 
Benzoic Acid,3-HO- A 4.09 
 
35 0.672 1.486 0.2163 6 102 93 0.99 92.1 1.49 -1.08 0.04 4 1.06 0.72 1.29 0.98 0.99 
 
[31] 
Benzoic Acid,3-NO2- A 3.40 
 
35 0.781 0.870 0.1656 6 91 54 
0.99
9 54.0 1.82 -1.62 0.09 6 0.64 0.54 1.65 1.02 1.11 
 
[31] 
Benzoic Acid,4-Br- A 3.98 
 
35 0.128 0.034 0.0029 5 11 3 0.71 2.1 2.85 -3.47 0.16 2 0.66 0.44 1.24 1.08 1.11 
 
[31] 
Benzoic Acid,4-Cl- A 3.84 
 
35 0.177 0.056 0.0029 6 13 4 0.87 3.5 2.74 -3.13 0.20 1 0.66 0.44 1.16 0.90 1.05 
 
[31] 
Benzoic Acid,4-CN- A 3.48 
 
35 0.578 0.318 0.0548 6 40 20 0.98 19.7 1.56 -1.90 0.20 1 0.66 0.59 1.56 0.92 1.09 
 
[31] 
Benzoic Acid,4-HO- A 4.32 
 
35 0.646 0.222 0.0161 6 19 14 0.98 13.8 1.57 -1.22 0.10 6 1.00 0.72 1.29 0.98 0.99 
 
[31] 
Benzoic Acid,4-MeO- A 4.44 
 
35 0.325 0.069 0.0040 6 14 5 0.85 4.3 1.95 -2.65 0.03 2 0.57 0.66 1.17 0.81 1.13 
 
[31] 
Benzoic Acid,4-NO2- A 3.31 
 





37 0.346 0.339 
 





25 0.312 0.314 0.003 4 66 20 0.97 19.4 2.45 -3.21 0.17 13 0.39 0.92 2.06 2.12 1.81 dihydrate [33] 
Carbamazepine N 
  





25 0.312 0.309 0.025 4 66 20 0.96 19.2 2.45 -3.21 0.17 13 0.39 0.92 2.06 2.12 1.81 CC (mixture) [33] 
Carbamazepine N 
  
25 0.312 0.298 0.007 11 63 19 0.97 18.5 2.45 -3.21 0.17 13 0.39 0.92 2.06 2.12 1.81 
CC (4-NH2-benzoic 
acid), pH 4.0 [6] 
Carbamazepine N 
  
25 0.312 0.348 0.017 7 72 22 0.98 21.6 2.45 -3.21 0.17 13 0.39 0.92 2.06 2.12 1.81 
CC (saccharin), pH 
2.2 [6] 
Alex Avdeef ADMET & DMPK 6(2) (2018) 105-139 
114  
 





(base) t(`C) k (calc) 
b k (obs) c ± SD N d log Kn 




S0  ±SD N  Σα2
H Σβ2
H π2 R2 Vx Comments Ref 
Carbamazepine N 
  
25 0.312 0.334 0.055 5 69 21 0.99 20.7 2.45 -3.21 0.17 13 0.39 0.92 2.06 2.12 1.81 
CC (salicylic acid), 
pH 3.0 [6] 
Carbamazepine N 
  
25 0.312 0.297 0.007 10 63 19 0.97 18.4 2.45 -3.21 0.17 13 0.39 0.92 2.06 2.12 1.81 
CC (succinic acid), 
pH 3.1 [6] 





7.75 37 0.020 0.051 0.001 5 22 4 0.79 3.2 4.14 -5.40 0.36 7 0.62 2.09 3.00 3.08 3.10 pH 1.2 [35] 
Carvedilol B 
 
7.75 37 0.020 0.061 0.002 5 23 4 0.94 3.8 4.14 -5.40 0.36 7 0.62 2.09 3.00 3.08 3.10 pH 3.0 [35] 
Carvedilol B 
 
7.75 37 0.020 0.064 0.005 5 23 4 0.99 3.9 4.14 -5.40 0.36 7 0.62 2.09 3.00 3.08 3.10 pH 4.5 [35] 
Carvedilol B 
 
7.75 37 0.020 0.061 0.006 5 23 4 0.94 3.8 4.14 -5.40 0.36 7 0.62 2.09 3.00 3.08 3.10 pH 5.8 [35] 
Carvedilol B 
 
7.75 37 0.020 0.063 
 
5 23 4 0.98 3.9 4.14 -5.40 0.36 7 0.62 2.09 3.00 3.08 3.10 pH 6.8 [35] 
Carvedilol B 
 
7.75 37 0.020 0.061 0.001 5 23 4 0.94 3.8 4.14 -5.40 0.36 7 0.62 2.09 3.00 3.08 3.10 pH 7.2 [35] 
Clofazimine B 
 
























3.41 24 0.146 0.261 0.003 3 66 17 0.95 16.2 2.99 -3.81 0.11 10 0.00 1.04 1.72 2.11 2.07 0.15M NaCl [36] 
Erythromycin B 
 
8.82 25 0.546 0.345 0.117 4 62 22 0.97 21.4 2.54 -2.75 0.26 4 1.05 4.63 3.04 2.51 5.77 
 
[37] 
Estradiol,17β- A 4.25 
 





25 0.061 0.035 0.008 4 18 3 0.72 2.2 5.23 -5.90 0.32 5 0.00 1.13 2.11 1.62 2.72 
 
[38] 
Glibenclamide A 5.30 
 




9 3.75 -6.54 0.44 10 0.85 2.01 3.84 2.64 3.47 
 
[39] 
Glibenclamide A 5.30 
 




5 3.75 -6.54 0.44 10 0.85 2.01 3.84 2.64 3.47 0.15M NaCl [39] 
Gliclazide A 5.49 
 
25 0.048 0.036 0.034 1 14 3 0.74 2.2 1.51 -4.35 0.32 5 0.59 1.66 2.54 1.93 2.28 
 
[39] 
Gliclazide A 5.49 
 
25 0.048 0.049 0.042 1 18 4 0.76 3.1 1.51 -4.35 0.32 5 0.59 1.66 2.54 1.93 2.28 0.15M NaCl [39] 
Glimepiride A 5.62 
 
25 0.004 0.010 0.010 1 7.4 1 0.65 0.6 2.94 -7.09 0.57 6 0.75 2.15 3.50 2.41 3.63 
 
[39] 
Glimepiride A 5.62 
 
25 0.004 0.020 0.020 1 14 2 0.63 1.3 2.94 -7.09 0.57 6 0.75 2.15 3.50 2.41 3.63 0.15M NaCl [39] 
Glipizide A 5.13 
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(base) t(`C) k (calc) 
b k (obs) c ± SD N d log Kn 




S0  ±SD N  Σα2
H Σβ2
H π2 R2 Vx Comments Ref 
Glipizide A 5.13 
 
25 0.016 0.011 0.010 1 5.8 1 0.67 0.7 2.01 -5.53 0.17 6 0.85 2.19 3.71 2.52 3.21 0.15M NaCl [39] 
Hydrocortisone N 
  
25 0.219 0.172 0.065 7? 35 11 0.97 10.7 1.61 -3.04 0.07 15 0.73 1.90 2.92 2.04 2.80 
 
[40] 
Ibuprofen A 4.25 
 
37 0.100 0.294 
 
1 68 19 0.96 18.2 4.13 -3.53 0.20 18 0.57 0.51 1.01 0.78 1.78 0.1M HCl, pH 1.2 [41] 
Ibuprofen A 4.24 
 
25 0.086 0.248 0.004 9 61 16 0.96 15.4 4.13 -3.70 0.20 18 0.57 0.51 1.01 0.78 1.78 
 
[42] 
Ibuprofen A 4.24 
 
27 0.086 0.362 0.017 5 87 23 0.98 22.4 4.13 -3.70 0.20 18 0.57 0.51 1.01 0.78 1.78 
 
[43] 
Ibuprofen A 4.24 
 
27 0.086 0.255 0.013 6 61 16 0.99 15.8 4.13 -3.70 0.20 18 0.57 0.51 1.01 0.78 1.78 
 
[44] 
Ibuprofen A 4.25 
 
37 0.100 0.409 0.016 6 93 26 0.98 25.4 4.13 -3.53 0.20 18 0.57 0.51 1.01 0.78 1.78 
 
[44] 
Indomethacin A 4.13 
 
37 0.021 0.024 0.000 6 11 2 0.73 1.5 3.51 -5.23 0.22 20 0.57 1.24 2.49 2.44 2.53 
 
[45] 
Ketoprofen A 4.00 
 
37 0.132 0.840 0.097 3 173 53 0.98 52.1 3.16 -3.23 0.25 19 0.57 0.87 1.97 1.56 1.98 pH 4.0 [46]  
Ketoprofen A 4.00 
 
37 0.132 0.946 0.093 3 193 59 0.99 58.7 3.16 -3.23 0.25 19 0.57 0.87 1.97 1.56 1.98 pH 4.6 [46]  
Ketoprofen A 4.00 
 
37 0.132 1.052 0.117 3 215 66 0.99 65.2 3.16 -3.23 0.25 19 0.57 0.87 1.97 1.56 1.98 pH 6.0 [46]  
Ketoprofen A 4.00 
 
37 0.132 1.091 0.045 3 222 68 0.99 67.6 3.16 -3.23 0.25 19 0.57 0.87 1.97 1.56 1.98 pH 6.8 [46]  
Loratadine B 
 
5.25 25 0.027 0.119 
 
1 42 8 0.92 7.4 5.20 -5.17 0.30 3 0.00 1.14 2.09 2.19 2.87 
 
[47] 
Mefenamic Acid A 4.19 
 
37 0.0089 0.0036 0.0002 8 5.6 1 0.22 0.2 5.12 -6.19 0.38 8 0.65 0.70 1.47 1.65 1.92 50 mM PO4 [41] 
Mefenamic Acid A 4.19 
 
37 0.0089 0.0044 0.0001 6 5.8 1 0.27 0.3 5.12 -6.19 0.38 8 0.65 0.70 1.47 1.65 1.92 
50 mM PO4 + 100 
mM NaCl [41] 
Mefenamic Acid A 4.19 
 
37 0.0089 0.0036 0.0003 6 5.6 1 0.22 0.2 5.12 -6.19 0.38 8 0.65 0.70 1.47 1.65 1.92 
50 mM PO4 + 50 
mM NaCl [41] 
Nimesulide A 6.31 
 
37 0.046 0.017 
 
1 8.8 2 0.52 1.0 2.39 -4.38 0.24 4 0.43 1.10 2.68 2.03 1.99 









1.90 24 0.111 0.167 0.003 3 46 11 0.94 10.3 2.24 -4.03 0.17 5 0.64 1.29 1.75 2.23 1.99 
 
[36] 
Paraben,Et- A 8.35 
 
24 0.313 0.478 0.017 3 70 30 0.99 29.7 2.47 -2.28 0.07 6 0.66 0.72 1.25 0.87 1.27 
 
[36] 
Paraben,Me- A 8.35 
 
24 0.476 0.561 0.037 3 66 35 0.99 34.8 1.96 -1.82 0.11 8 0.66 0.72 1.24 0.87 1.13 
 
[36] 
Paraben,Me- A 8.35 
 
24 0.476 0.340 0.010 3 41 22 0.96 21.1 1.96 -1.82 0.11 8 0.66 0.72 1.24 0.87 1.13 0.15M NaCl [36] 
Paraben,n-Bu- A 8.47 
 





3.58 25 0.192 0.085 0.006 5 22 6 0.88 5.3 2.60 -3.59 0.03 1 0.35 0.74 1.78 2.12 1.40 pH 1.0 [49]  
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(base) t(`C) k (calc) 
b k (obs) c ± SD N d log Kn 




S0  ±SD N  Σα2
H Σβ2
H π2 R2 Vx Comments Ref 
PG-300995 B 
 
3.58 25 0.192 0.082 0.003 9 7 6 0.00 5.1 2.60 -3.59 0.03 1 0.35 0.74 1.78 2.12 1.40 pH 2.0 [49]  
PG-300995 B 
 
3.58 25 0.192 0.081 0.004 5 19 6 0.00 5.0 2.60 -3.59 0.03 1 0.35 0.74 1.78 2.12 1.40 pH 3.0 [49]  
PG-300995 B 
 
3.58 25 0.192 0.022 0.001 5 7.5 2 0.68 1.4 2.60 -3.59 0.03 1 0.35 0.74 1.78 2.12 1.40 pH 7.0 [49]  
Phenytoin A 8.28 
 
25 0.063 0.023 0.0002 4 8.5 2 0.73 1.5 2.24 -4.05 0.11 21 0.44 1.14 2.04 1.94 1.87 
 
[50] 
Pioglitazone AB 5.63 6.63 25 0.028 0.023 0.023 1 13 2 0.72 1.4 2.94 -6.32 0.23 2 0.34 1.64 2.37 2.33 2.66 
 
[39] 
Pioglitazone AB 5.63 6.63 25 0.028 0.026 0.025 1 13 2 0.80 1.6 2.94 -6.32 0.23 2 0.34 1.64 2.37 2.33 2.66 0.15M NaCl [39] 
Piroxicam AB 1.76 4.96 37 0.023 0.019 0.001 3 8.8 2 0.58 1.2 1.98 -4.33 0.33 18 0.72 2.12 3.12 2.56 2.16 pH 4.0 [51] 
Piroxicam AB 1.76 4.96 37 0.023 0.020 0.002 3 8.8 2 0.60 1.2 1.98 -4.33 0.33 18 0.72 2.12 3.12 2.56 2.16 pH 5.0 [51] 
Piroxicam AB 1.76 4.96 37 0.023 0.018 0.002 3 8.8 2 0.55 1.1 1.98 -4.33 0.33 18 0.72 2.12 3.12 2.56 2.16 pH 6.0 [51] 
Piroxicam AB 1.76 4.96 37 0.023 0.031 0.0004 3 10 2 0.96 1.9 1.98 -4.33 0.33 18 0.72 2.12 3.12 2.56 2.16 pH 7.0 [51] 
Piroxicam AB 1.76 4.96 37 0.023 0.018 0.044 3 8.8 2 0.56 1.1 1.98 -4.33 0.33 18 0.72 2.12 3.12 2.56 2.16 pH 7.8 [51] 
Prazepam B 
 















24 0.139 0.150 0.001 3 46 10 0.93 9.3 3.77 -4.53 0.22 12 0.00 1.04 2.49 1.56 2.62 0.15M NaCl [36] 
Progesterone,11-α-HO- N 
  
24 0.122 0.276 0.007 3 82 18 0.95 17.1 2.36 -4.51 0.39 5 0.31 1.35 2.75 1.77 2.68 
 
[36] 
Repaglinide AB 3.83 6.20 25 0.034 0.038 0.037 1 15 3 0.79 2.4 4.69 -4.89 0.16 2 0.83 1.71 2.77 2.17 3.68 
 
[39] 















25 0.097 0.033 0.001 4 11 3 0.68 2.1 3.14 -3.57 0.18 7 1.50 1.04 1.82 1.97 1.74 pH 8.0, 2M urea [52] 
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(base) t(`C) k (calc) 
b k (obs) c ± SD N d log Kn 




S0  ±SD N  Σα2
H Σβ2
H π2 R2 Vx Comments Ref 
Rosiglitazone AB 6.23 6.51 25 0.027 0.032 0.030 1 12 2 1.00 2.0 2.56 -5.05 0.24 2 0.34 1.88 2.64 2.55 2.61 0.15M NaCl [39] 
Salicylic Acid A 2.84 
 















25 0.181 0.115 0.060 7? 34 8 0.89 7.1 3.31 -4.09 0.07 13 0.31 1.01 2.27 1.55 2.38 
 
[40] 
Toluic Acid,3- A 4.26 
 
35 0.865 1.199 0.009 6 124 75 0.99 74.3 2.39 -1.63 0.38 3 0.57 0.44 1.02 0.77 1.07 
 
[31] 
Toluic Acid,4- A 4.35 
 





3.60   25 0.087 0.313 0.005 8 75 20 0.97 19.4 3.90 -3.69 0.36 4 1.21 1.82 3.32 2.96 3.41   [53] 
a
  Kn = drug-micelle binding constant, where n drugs are bound to one micelle; Nd = average number of bound drugs per micelle; fbm =  fraction of drug-bound micelles; 
    Poct = octanol-water partition coefficient;  S0 = intrinsic solubility, average of N published values;  Σα2
H
, ... , Vx are the calculated Abraham solvation descriptors (cf., Glossary). 
b
 Calculated from expressions in Table 2. 
e
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With water solubility determined from the horizontal portions of the curves (or taken from literature 
sources), and with the k values determined from the micellar portions of the plots, it was possible to 
approximate the drug-micelle binding constants, log Kn, according to Eq. (13). The stoichiometric coefficient, n, 
was selected according to Eq. (14). These estimated results are listed in Table 1.  
Prediction Model for k Values 
In a comprehensive study, Abraham et al. [58] considered the SDS-water partitioning of a large number of 
molecules (e.g., gases, common solvents, polycyclic aromatics, carboxylic acid and phenol derivatives, etc.) and 
developed tight prediction equations based on octanol-water partition coefficients, as well as the five 
Abraham solvation descriptors (r
2
 = 0.97, SD = 0.17 log unit, F = 817, N = 132). The micelles were treated as a 
separate phase in the two-phase (aqueous-micellar) media. The SDS-water partition coefficients, PSDS-water, can 
be converted into k values, as mentioned above [12]. Apparently, the prediction study had not been extended 
to drug molecules which precipitate in SDS-containing solutions to form three-pseudophase systems (aqueous, 
solid, micellar). By contrast, attention in the present study was directed mainly towards poorly-soluble drug 
molecules (Table 1). As the discussion has stressed, a drug-micelle binding paradigm (i.e., mass action model) is 
used here, rather than a partitioning approach chosen by Abraham et al. [58].  
Several comparisons were made in an attempt to find predictive correlations between k and other 
commonly-available physicochemical descriptors. Figure 8a shows the plot of measured log k values as a 
function of octanol-water partition coefficients, log Poct. The trend suggests that solubilization capacity of drugs 
decreases as lipophilicity increases, but the correlation is clearly weak. A similar trend, albeit with only slightly 
improved correlation, is noted when log k is plotted against size of molecules in Figure 8b. For smaller sets of 
homologous compounds, better correlations have been observed. For example, Fahelelbom et al. [30] 
reported r2 = 0.85 for the correlation between k and molar volume for six iminophenazine derivatives (cf., six 
squares for log k < -3 in Fig. 8b). 
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Figure 2. Examples of micellization plots of nonionizable drugs. The CMC values span from 4.6 to 9.6 mM, which 
suggests that the drugs had only a small influence on the onset of micelle formation with increasing SDS additions 
to distilled water.  The [SDS] > CMC curves show slight curvature for artemisinin, carbamazepine, and fenofibrate.  
These are the cases of [SDS] exceeding 40 mM, which may suggest a saturation/decrease of the capacity to bind 
these uncharged drugs. The n values in Table 1 indicate that 19-22 carbamazepine molecules bind to a single 
micelle above the CMC. The n values for artemisinin, 11α-hydroxyprogesterone, and testosterone are estimated 
to be 12, 18, and 13, respectively. Just 3 fenofibrate bind to one SDS micelle, given that the drug is so poorly 
soluble (0.0013 mM). The solubility of the other drugs ranges from 0.03 to 0.93 mM. The drug-micelle binding 
constants, Kn (cf., Eq. (13)), range from 10
+18




 (11α-hydroxyprogesterone). Pure 
carbamazepine or carbamazepine released from cocrystals appears to indicate the same micellization slopes.  
Also, the slopes at 25 and 37 °C appear to be nearly the same for the drug. 
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Figure 3. Examples of micellization plots of largely nonionized acidic drugs.  In the first seven frames, the medium 
was distilled water. In Figure 3h, HCl was added to adjust the solution to pH 2 (where salicylic acid is largely 
uncharged). In Figure 3i, 3 mM phosphate buffer at pH 7.4 was used, although pDISOL-X calculation suggests that 
in the low buffer capacity solution, the pH may have been as low as 4.2  (the final pH values of the valsartan 
solutions were not reported). In these cases, it was assumed that ionization of the acids was insignificant. Most of 
the CMC values are in the interval 2.4-8.2 mM. The micellar-portion curves show slight curvature for phenytoin (g) 
and salicylic acid (h), as the surfactant concentrations extend to 277 and 173 mM, respectively. Indomethacin (f) 
also extends to high surfactant concentrations (238 mM) but does not indicate nonlinearity. In the plots of 
indomethacin and valsartan, the CMC is very close to zero. The data in the case of ibuprofen (e) show peculiar 
variance, for [SDS] < 7 and > 15 mM. Four of the low-soluble compounds bind as 2 drugs per micelle, with Kn 
ranging from 10
+8.5
 (phenytoin) to 10
+16
 (curcumin). Values of n for the more soluble drugs range from 20 






, respectively (cf., Table 1). 
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Figure 4. Examples of micellization plots of largely nonionized basic drugs. Erythromycin (b) and NSC-639829 (c) 
show curvature in the micellar portion of the curves, even over relatively low surfactant concentrations. 




(Eq. 13). The most insoluble of the bases, NSC-639829, binds 




. The other values of n range from 10 to 26 (cf., Table 1). 
 
Figure 5. Examples of the effect of salt on micellization. With the apparent exception of buffered solutions of 
mefenamic acid (S0 = 0.6 μM) and, to a lesser extent, of resveratrol (S0 = 180 μM), the examples comparing water 
to 0.15 M  NaCl solutions show that k values decrease with increasing salt. Also, the CMC decreases with 
increasing salt concentration, an effect expected from properties of SDS in the absence of drug, as illustrated in 
Figure 1. With lower CMC, the micelle structures become more stabilized due to reduced head group charge 
repulsions, which lead to reduced drug solubilization. The addition of buffer, as in the cases of mefenamic acid (b) 
and resveratrol (e) contributes to the ionization of the drugs, which impacts on the solubility, but not so much on 
the solubilization capacity. 




Figure 6. Example of the effect of temperature on micellization. Ibuprofen shows higher degree of solubilization at 
37 °C (26 drugs/micelle, Table 1), compared to 27 °C (16 drugs/micelle). The CMC is only slightly elevated at the 
higher temperature. The formation of micelles is entropy driven, due to the release of water structure 
surrounding hydrophobic groups, as these groups migrate into the micelle core [12]. Above 60 °C, water 
loses most of its ability to form cavities around hydrophobic groups, so the drive to form micelles is 
weakened at elevated temperature, indicated by increased CMC [11, 12]. Urea also plays a role in “water 
structure breaking.” 
 
Figure 7. Examples of effect of pH on micellization. When pH of the medium is adjusted with buffers, the 
calculated water solubility needs to take into account the pKa of the molecule. Sub-CMC data for carvedilol (b) 
and PG-300995 (e) are not shown, as these involve the precipitation of the cationic drugs and the anionic 
surfactant. With the added complexity, these molecules are further discussed in a separate section below. With 
the exception of PG-300995 (e), the k values do not show appreciable dependence on pH, as indicated in frames 
(b), (d), and (f). The mass action equilibrium model can rationalize the k -pH dependence of PG-300995 (below). 
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A significantly improved correlation (r
2
 = 0.69) is evident between measured log k and log S0, as shown in 
Figure 8c. This might have been anticipated by Eq. (13). The standard deviation, SD = 0.50 log unit, is 
suggestive of the 0.6-0.7 log unit often cited interlaboratory reproducibility in drug solubility measurement, 
although reproducibility could be improved if the solubility data were critically processed [55]. An examination 
of Figure 8c suggests that acids (red circles) tend to distribute below the correlation line for S0 > 1 μM, 
suggesting that acid-base properties might correlate with k values. 
To test the k data for further relationships, the 101-molecule set was subdivided into four groups, 
differentiated by acid-base indicator indices (0/1), IA, IB, IAB, IN, to designate each drug as an acid, base, 
ampholyte, or neutral type, respectively (Table 1). Each k sub-group of drugs was tested separately, using 
log S0, and just one of each of the five Abraham [59] solvation descriptors (Σα2
H, Σβ2
H: H-bond acidity and 
basicity; π2: dipolarity/polarizability; R2: dispersion force; and Vx: molar volume – see Glossary for further 
elaboration; Table 1 lists the five descriptors). The five descriptors were estimated from the 2D structure of 
molecules. Table 2 lists the results of the best-fitting combination of descriptors (no more than two per acid-
base sub-group). Inclusion of Abraham H-bond descriptors only slightly improved the fitting (r
2
 increased from 
0.69 to 0.74). Generally, the distribution of solute between the water, solid, and micelles is tilted towards the 
solid state for highly insoluble drugs, as evidenced by decreased solubilization capacity. In the case of acids, 
strong H-bond donor character leads to decreased solubilization capacity; for non-ionizable drugs and for 
ampholytes, strong H-bond acceptor character leads to decreased solubilization by SDS. In the case of 
ampholytes, most of the variance is accounted by Σβ2
H
, while log S0 appears to be of minimal importance 
(Table 2).  
Figure 8d shows the final best-fit model correlation plot (although it is hardly better than that in Fig. 8c). 
The four acid-base group analyses were combined into a single multiple linear regression (MLR) equation: 
log k = { c0 + c1 · log S0 + c2 · Σα2
H } · IA  + { c3 + c4 · log S0 } · IB   
                                   + { c5 + c6 · log S0 + c7 · Σβ2
H
 } · IN   + { c8 + c9 · log S0 + c10 · Σβ2
H
 } · IZ (15) 
 
Table 2.  Prediction of k values a 
Class Equation r2 SD F N 
Nonionizables   log k =  0.479 + 0.249 log S0 -0.201  Σβ2
H
 0.70 0.15 17 17 
Acids   log k =  1.011 + 0.417 log S0 -0.692  Σα2
H
 0.71 0.49 54 47 
Bases   log k =  1.228 + 0.542 log S0  0.74 0.57 66 25 
Ampholytes   log k = -0.122 + 0.083 log S0 -0.548  Σβ2
H
 0.79 0.10 17 12 
Overall based on Eq. (15) 0.74 0.44 288 101 
a
  Σα2H and  Σβ2H are the calculated Abraham H-bond total acidity and basicity descriptors, resp.; 
   r
2
 = squared multiple correlation coefficient;  SD = standard deviation in the linear fit; 
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Figure 8. Correlations between log k and (a) octanol-water partition coefficients, log Poct, (b) McGowan molecular 
volume, Vx, in units of 0.01 L·mol
-1
 (c) intrinsic solubility, log S0 (molarity), and (d) multiple linear regression with 




 as descriptors (cf., Table 2). 
 
The best-fit MLR coefficients, c0-c10 are listed in Table 2. The combined set yielded r
2 = 0.74, SD = 0.44, F = 
288, N = 101. The compounds with the lowest intrinsic solubility (e.g., NSC-639829, curcumin, glibenclamide) 
showed the highest variances, as indicated in Figure 8d. The erythromycin outlier may be due to unaccounted 
precipitation of the drug-SDS salt [61]. In sum, it appears that the combined quality of the experimental k and 
S0 data limited further improvements of the prediction model.  
In-Depth Treatment of pH Dependence of k Values 
 The data below the CMC for carvedilol (Fig. 7b) and PG-300995 (Fig. 7e) take on a complex dependence on 
pH and SDS concentration, and will be examined here in detail. As the SDS decreases below the CMC, the 
solubility of the two molecules actually increases, in contrast to all the preceding examples (Figs. 2-6). This can 
be explained by the precipitation of salt formed between positively charged drug and the SDS anions, and 
confirmed by speciation regression analysis. The same may be taking place for carbendazim at pH 2.05 in 
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Figure 7a, but there was not enough data reported to test this. However, there were sufficient pre-CMC 
measurements in the cases of carvedilol and PG-300995, particularly in the latter case. 
Carvedilol 
Chakraborty et al. [35] studied the micellization of carvedilol at 37 °C in the pH 1.2-7.2 range, where the 
drug was largely positively charged. The authors suggested that anionic SDS interacted with the cationic drug 
species to form an insoluble drug salt. The k values (Fig. 7b) did not change across the pH range considered, 
which is expected if only the neutral form of the drug were solubilized by SDS micelles. There were not a lot of 
data in the pre-CMC region, but it was possible to estimate log Ksp
BH.Cl
 = -3.88 (from surfactant-free solubility 
data) and log Ksp
BH.SDS 
= -5.52 (from data at [SDS]tot = 5 mM). 
PG-300995 
 There were ample data, both pre- and post-CMC, for the case of PG-300995 (2-(2-Thienyl)-1H-imidazo[4,5-
b]pyridine) reported by Jain et al. [49] to allow for further analyses here. The solubility-pH data at 25 °C, 
I = 0.2M, in SDS-free, buffered solutions [60] were re-analyzed using pDISOL-X, to obtain pKa = 3.59 ± 0.06, 
log S0 = -3.59 ± 0.03, and log Ksp
BH.Cl 
= -2.12 ± 0.11, GOF = 0.84, n = 11. Jain et al.[49] had proposed that the 
positively-charged drug precipitates as the (estolate) salt with anionic SDS in the pre-CMC region. 
Erythromycin is another rare example of such an estolate salt formation [61]. However, the solubilization of 
the salt is not evident in Figure 4b. It is estimated that the solution pH is 9.7 (not reported by Bhat et al. [37]).  
 The PG-300995 data across the whole range of SDS concentrations were analyzed by the mass action 
model, employing one heterogeneous and three homogeneous equilibrium equations. The drug is uncharged 
at pH 7, and the micellization behavior is relatively simple. Figure 9a shows the drug solubility as a function 
[SDS]tot. The red curve was calculated using the mechanistic model described by Eqs. (2)-(4), with n = 2. (This is 
nearly, but not precisely, the same as the empirical fit of the pH 7 curve in Figure 7e.) The best-fit constants 
are summarized in the box in Figure 9c. Figure 9b shows the underlying reactant concentrations. These 
concentrations largely follow the pattern shown in Figure 1a. The solubilization of uncharged drug lowers the 
CMC to 3.2 mM. This relatively simple pattern of concentrations is expected to be repeated in the examples in 
Figures 2-6, where the drug in solution is predominantly in the uncharged state. However, the data patterns 
for PG-300995 at pH 1-3 are quite different, where the drug in solution is predominantly positively charged.  
One of the independent variables in the mass action calculations is the actual weight of the API added to 
solution. Provided enough solid is added to maintain a saturated solution, knowledge of the exact weight is 
not critical for simple solubilization reactions in drug-saturated solutions under conditions where the drug is 
uncharged (i.e., at pH 7). Most publications simply state that “excess solid” was added in the solubility assay. 
The PG-300995 publication falls into this category. However, at pH 1-3, the PG-300995 reactions are not 
simple. When the cationic drug, BH+, forms a salt precipitate with SDS-, then it is necessary to provide the exact 
analytical weight of the API for the calculation. 
Figure 10a shows the drug solubility at pH 1 as a function [SDS]tot. Three different [PG]tot were tested in the 
mass action calculations: 15, 30, and 38 mM (solid, dot, dash curves, resp.). Above the CMC (estimated at 17 
mM), it is not critical to the calculation that the actual [PG]tot be provided. “Excess” is sufficient. There, the 
linear increase in solubility with increasing SDS is compatible with four protonated drugs bound per micelle 
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aggregate. Eq. (13) cannot be used, as noted earlier. The red dashed (38 mM) best-fit curve matches the data 
at the two lowest and the four highest [SDS]tot points (squares), but not the three points in the middle. The 
refinement of equilibrium constants (at 38 mM) was carried out by assigning zero weights to the latter three 
















Figure 9. Mass action analysis of the solubilization of PG-300995 at pH 7, where the drug is uncharged. (a) Total 
drug solubility vs. {SDS]tot, (b) speciation profile, (c) mass action model summary (B = PG-300995). 
The mass action model consisted of three homogeneous and three heterogeneous equilibria, summarized 
in the box in Figure 10c. For the entire range of SDS values, the precipitated form of the drug is the estolate 
salt. The hydrochloride salt was included in the analysis, but the data did not support its role in this 
complicated solubilization system. Figure 10b displays the underlying reactant and complex species formed 
with increasing SDS for 15 mM total added drug. The curves for some of the species were scaled in order to 
appear in the same view. The CMC break in the curves occurs at 17 mM, corresponding to an unusually 
elevated value, suggesting a weakened micellar structure compared to drug-free conditions. 
Stabilizing Cocrystal Suspension with SDS 
Carbamazepine:Saccharin 1:1 Cocrystal – Experimental Data from Cao et al. [9] 
 There are very few published examples [9, 33] of eutectic data for both the API and the coformer in assays 
where surfactant had been added. Cao et al. [9] published an in-depth mechanistic dissolution study of the 
carbamazepine:saccharin 1:1 cocrystal system, which included such eutectic data for both carbamazepine and 
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saccharin at pH 1 in the presence of 22, 44, 250, and 400 mM SDS. The CC system had been thoroughly studied 

















Figure 10. Mass action analysis of the solubilization of PG-300995 at pH 1, where the drug is positively charged. 
(a) Total drug solubility vs. [SDS]tot at three levels of total drug concentration, (b) speciation profile at 15 mM total 
drug concentration, (c) mass action model summary (B = PG-300995). 
 The non-CC carbamazepine solubility-SDS data at 25 °C [6] in Figure 2d were subjected to mass action 
analysis to determine the best-fit drug-micelle binding constant, and to attempt to predict the curvature in the 
post-CMC plots. It was assumed that 22 carbamazepine molecules bind to one SDS micelle aggregate (cf., 
Table 1). At least three constants were needed to explain the data pattern in Figure 2d: log KSDS = 230.6,  
log K22 = 74.0, log S0 = -3.33, GOF = 0.50, N = 37. There was a tiny bend in the calculated mass action post-CMC 
curve (due to ionic strength effects), but not fully matching the extent of the curvature observed for  
[SDS]tot > 70 mM, where solubilization capacity notably decreased. This was expected to complicate the 
quantitative assessment of the eutectic data of Cao et al. [9], who considered [SDS]tot as high as 400 mM. 
 From the non-SDS carbamazepine:saccharin 1:1 CC solubility-pH data, the mean of the equilibrium 
constants reported previously [17, 63, 64] are pKa
cof = 1.31, log Ksp = -6.01 and log S0 = -3.26. One additional 
constant was needed, Kn
cof, before the Cao et al. eutectic solubility data could be processes by pDISOL-X. The 
formula for acids in Table 2 predicted the k value of saccharin to be 0.516. The product of kNagg suggested that 
ncof = 32 (Eq. 14). From Eq. (13), the log Kn
cof was estimated as 58.9.  
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As the last step, the eight eutectic concentration data (in 22-400 mM SDS [9]) were subjected to a series of 
pDISOL-X analyses to determine the API and the coformer-micelle binding constant, following procedures 
described in detail elsewhere [16, 17]. The mean constants in the preceding paragraph were introduced as 
fixed parameters, and were not refined. The estimated Kn
cof constant indicated that the concentration of the 
saccharin-micelle species maximized at pH 1.7 but did not exceed 10
-9
 M; thus the constant was not subjected 
to refinement. Only log Kn was refined. The Appendix defines the function minimized and the goodness-of-fit 
(GOF) statistic.  
The analysis of the Cao et al. data encountered an unexpected complication. The refined constant, Kn, 
depended critically on the actual weights of API and coformer added to the solutions. The original publication 
stated the quantities as ranges: 100-150 mg CC and 50-100 mg excess carbamazepine in 3 mL solution. Various 
combinations of weights were tried within/near the specified ranges. The minimum GOF 0.79 was found near 
70 mg/mL CC + 35 mg/mL excess API. The refined constant, log K22 = 84.0, somewhat higher than the value 
obtained from non-CC data.  
 Figure 11 shows the eutectic curve and speciation plots for the cocrystal system for the [SDS]tot of 0, 22, 
44, 250, and 400 mM. It was a complicated calculation. In frames (a)-(c)/(f)-(h), eutectic conditions hold up to 
pH 3, above which, the cocrystal dissolves but carbamazepine precipitate persists. Up to 44 mM SDS, the 
coformer eutectic curves are relatively unchanged, as the API curves are lifted by the added SDS, creating 
cross-over points in frames (b) and (c) at pH 1.7 and 2.2, respectively. At the two highest SDS concentrations, 
the cross-over is no longer evident, and even the coformer eutectic curves show upward lift (suggesting 
coformer-micelle complexes play a role). The 250 mM SDS is sufficient to dissolve the excess API at low pH, to 
form a “eutectoid” state (only CC precipitates; cf. Glossary), but only up to pH 2.69 (Fig. 11i). Between pH 2.69 
and 2.90, a narrow eutectic state is predicted to form, as the SDS cannot suppress some API from precipitating. 
Above pH 2.9, the API remains the only residual solid in the suspension, as all of the CC dissolves. At the 
highest SDS concentration, the API is entirely micellized across the whole pH range. The eutectoid zone is 
thermodynamically stable up to pH 2.32, above which all solids dissolve (Fig. 11j). The same sample weights 
and the same equilibrium constants were used for all of the SDS-containing solutions. 
Atazanavir:Pterostilbene 1:1 Cocrystal – Exploratory Simulation of an Unmeasured System 
 Given that one can predict k and Ksp
CC, it was of interest to consider if a cocrystal between atazanavir and 
pterostilbene could form. There are no reports of such a system in the literature. Two main sets of conditions 
were explored in the simulated data: atazanavir cocrystal added to solution with and without excess drug. In 
each case, 0, 10, and 20 mM [SDS]tot were part of the simulation compositions. The equilibrium constants 
(37 °C) used in the calculations are listed in Figure 12a. The pKa and S0 were determined by analysis of the 
atazanavir-SDS data from Indulkar et al. [20]. The pterostilbene S0 was determined from data in [65], using the 
pKa
cof estimated from 2D structure. Cocrystal Ksp was estimated by the method described elsewhere [17]. Kn 
was estimated by Eq. (13). In the simulations in Figure 12, all cases were based on 100 mg/mL CC added to 
water, with pH adjusted using either 1 M HCl or NaOH. In the Figure 13 cases, excess API, 50 mg/mL, was 
added to the simulated solutions, in addition to the 100 mg/mL CC.  
Figure 12a shows the predicted eutectoid-eutectic concentration curves for the system in the absence 
surfactant. Below pH 3.23, the system is thermodynamically stable as a eutectoid (cf., Glossary). The eutectoid 
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concentration of atazanavir is lower than that found in non-CC systems. That of the pterostilbene is largely 
elevated from its non-CC value. Above pH 3.23, the cocrystal system unstitches into non-equivalent eutectic 
API and coformer concentrations, with the API taking on the thermodynamic values observed in the non-CC 
system. Concomitantly, API precipitates. The thick dashed purple, marking SCC, suggests an enhanced, albeit 
transient, concentration of the API. Adding the SDS, as in frames (b) and (c) has the effect of “zippering” the 
eutectic to a eutectoid state, to pH 8.62 in the case of 10 mM SDS and 9.79 in the case of 20 mM SDS. This has 
the effect of re-dissolving the API solid precipitated in the absence of the surfactant. 
 Figure 13 shows the simulated atazanavir:pterostilbene system where the CC is added along with an 
excess of API. The main effect is to “unzipper” the eutectoid states suggested in Figure 12. The middle-pH 
region in Figure 13b is nearly eutectoid, but not precisely so. 
 The simulations in the above two figures illustrate the kind of exploratory investigations that can be 
performed quickly in silico, as part of a plan to investigate a potential cocrystal system. 
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Figure 11. Carbamazepine:saccharin 1:1 cocrystal 
(data points from [9] and [64]). In all cases, the 
added CC and excess API weights were assumed to 
be 70 mg/mL and 35 mg/mL, respectively. The 
constants used (25 °C, Iref = 0.2 M) were: pKa
cof
 = 
1.31, log Ksp = -6.01, log S0 = -3.26, log K32
cof
 = 58.9, 
and log K22 = 84.0. (a)-(e): The log Ctot-pH profiles 
as thick solid red ([API]tot) and blue ([cof]tot) curves 
refer to the calculated (best-fit) total aqueous 
concentrations in saturated solutions containing 
increasing concentrations of SDS. The symbols: red 
circle ([API]tot,eu) and blue square ([cof]tot,eu) refer 
to the reported eutectic total concentrations [9, 
64]. The thick dashed purple curve (bounded by 
the API and coformer curves) refers to the 
calculated SCC. (f)-(j): The log speciation-pH 
profiles relate the concentrations of various 
(reactant and product) species to pH. The color 
assignments are the same as before. The thick 
solid curves refer to the carbamazepine (log [API0]) 
and the uncharged form of saccharin (log [cof0]). 
The corresponding charged forms are indicated by 
dash-dot curves. The vertical dashed lines mark 
cocrystal pH boundaries of the eutectic and 
eutectoid zones. The dotted curves 
ascending/descending from log C = 0 upper limit, 
indicated by black ❶ in the case of the CC and red 
❷ in the case of the API, are computational 
“virtual” concentrations of solid, a tracking tool 
designed to anticipate the approach to the onset 
of a new precipitate (as log C ascends to 0), or the 
complete dissolution of a solid (as the virtual log C 
descends from 0) 
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Figure 12.   Hypothetical atazanavir:pterostilbene 1:1 cocrystal system simulated in the study, where 100 mg/mL 
cocrystal are added to an aqueous solution containing 0, 10, and 20 mM SDS.  The symbols and curves are defined 
in Figure 11.  The upper thin blue dashed curve refers to the log S-pH profile expected of pterostilbene in absence 
of the API, and is calculated using the Henderson-Hasselbalch equation. The lower thin red dashed curve refers to 
the log S-pH profile expected of atazanavir in absence of the coformer.   
 
Figure 13.   Hypothetical atazanavir:pterostilbene 1:1 cocrystal system simulated in the study, the same system as 
in Figure 12, except that 100 mg/mL cocrystal plus 50 mg/mL atazanavir are added to aqueous solutions 
containing 0, 10, and 20 mM SDS.        
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Summary 
This review considered the uses of the anionic surfactant, sodium dodecyl sulfate (SDS), to mitigate poor 
bioavailability of some drugs due to their low aqueous solubility. A small database of 101 drug solubilizing 
capacity (k) values was compiled from published sources, from which a k predictive model was derived. The 
mass action paradigm was used to describe drug-micelle equilibrium reactions in aqueous-micellar-solid 
media, as a function of pH, ionic strength, and quantities of reactants used. The k values were converted to 
drug-micelle stoichiometric binding constants, Kn, corresponding to drug-micelle equilibria in drug-saturated 
solutions, with n values (Table 1) ranging from 1 (e.g., practically-insoluble drugs: atazanavir, clofazimine, 
glibenclamide, mefenamic acid) to over 50 (e.g., small substituted benzoic acids, ketoprofen, 3-toluic acid). The 
Kn values were further refined by generalized regression analysis in select cases. In the absence of drug, the 
monomer-micelle cumulative equilibrium, 62 SDS- + 50 Na+  SDS62Na50
12-, was consistent with the critical 
micelle concentration (CMC) of 8.3 mM for the aggregation constant log KSDS = 230.6. Also, this constant 
correctly predicted the CMC values as a function of added NaCl. The effect of drug on the above equilibrium 
was considered in select cases. An in-depth case study of the weak base, PG-300995 [24, 49, 60], considered 
the micellization reactions as a function of pH. At pH 1 the drug-SDS salt was predicted to precipitate both 
below and above the CMC. At very low SDS concentrations, the chloride salt was predicted to co-precipitate 
with the drug-SDS salt. Both solubility products were determined in the analysis of the reported solubility-
surfactant data. Above the CMC, in a rare example, the charged form of the drug was strongly solubilized: 4 
BH+ + SDS62Na50
12-  (BH)4SDS62Na50
8-, with the estimated binding constant, log Kn = 23.0. At pH 7, only the 
neutral form of the drug was solubilized, with log Kn = 7.4 (n=2). Also considered were examples of 
solubilization of solids in the form of cocrystals. The case studies included the carbamazepine:saccharin 
system, whose experimental data were analyzed to determine the binding constants. A recently-described 
method for predicting the solubility product of cocrystals (coupled with predicted k values described here) 
allowed for simulations of solubility-pH speciation profiles of cocrystal systems in the presence of SDS. Purely 
on in silico grounds, atazanavir was postulated to form a cocrystal with pterostilbene. This remains to be 
validated experimentally. Data patterns depending on the amount of SDS added and the extent of drug excess 
over the cocrystal amount added to solution were explored in silico.  
Conclusion 
The main objective of the study was to apply simulation methods to represent drug-micelle equilibrium 
reactions (based on the mass action paradigm), so as to optimize the design of experimental approaches used 
to assess drug solubility as a function of pH and the amount of added sodium dodecyl sulfate, particularly 
when applied to cocrystal formulations. In this endeavor, a new prediction model for the drug solubilization 
capacity (k) of sodium dodecyl sulfate was described. Well in advance of any actual measurements, these 
simulations can be used to probe conditions favorable to the design of experiments where SDS can stabilize 
cocrystal suspensions against drug precipitation over a range of pH values, in an effort to improve the rate and 
extent of oral absorption of the drug. 
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Glossary 
API active pharmaceutical ingredient, i.e., the ‘drug’ molecule 
coformer “generally regarded as safe” soluble molecule that can combine with an API to form a cocrystal 
[API0] ([cof0]) concentration of the neutral form of API (or coformer) determined from eutectic and/or 
eutectoid data 
[API]tot,eu(eo) measured equilibrium total aqueous concentration of the API at a eutectic (or eutectoid) point 
in a solution with a particular pH; e.g., points indicated as red circles in Figs. 3-5 
[cof]tot,eu(eo)  measured equilibrium total aqueous concentration of the coformer at a eutectic (or eutectoid) 
point with a particular pH; e.g., points indicated as blue squares in Figs. 3-5 
eutectic (eu) 3-phase system comprising a stable suspension containing both CC and crystalline API (or 
coformer) in contact with a saturated aqueous solution with both API- and coformer-
containing species at a particular pH 
eutectoid (eo) “sub-eutectic” point with thermodynamically stable CC and suppressed API and coformer 
precipitation:  2 phase system comprising a stable suspension containing just the CC in contact 
with a saturated aqueous solution with both API- and coformer-containing species at a 
particular pH; system may form even when CC plus API/coformer solids are added to water 
SDS (SLS) sodium dodecyl sulfate (i.e., sodium lauryl sulfate) 
CMC critical micelle concentration 
Nagg micelle aggregation number (62 for SDS is assumed) 
Nd average number of bound drugs per micelle 
fbm    fraction of drug-bound micelles 
Kn drug-micelle binding constant, where n drugs are bound to one micelle 
KSDS  micelle aggregation constant (cf., Eq. 1) 
S solubility, ideally expressed in units of mol/L (M) or mg/mL  
S0 “intrinsic” solubility (i.e., the solubility of the uncharged form of the compound) 
Sw “water” solubility, defined by dissolving enough pure free acid/base (not drug salt) in water (or 
water containing an inert salt - as ionic strength adjustor) to form a saturated solution 
SCC solubility of CC; if a eutectoid system forms by adding excess CC (without additional API or 
coformer) to pH-adjusted water, then SCC
 = [API]tot,eo = [cof]tot,eo; e.g., curves indicated by purple 
thick dashed lines in Figs. 11-13. 
S0
API (S0
cof) intrinsic solubility in a non-CC 2-phase system, where the crystalline API (or coformer) is in 
equilibrium with a saturated solution of the neutral API (or coformer) 
Σα2
H Abraham descriptor – solute H-bond total acidity (also called A)  
Σβ2
H Abraham descriptor – solute H-bond total basicity (also called B)  
π2 Abraham descriptor – solute polarity/polarizability due to solute-solvent interactions between 
bond dipoles and induced dipoles (also called S)  
R2 Abraham descriptor – excess molar refraction (L·mol
-1 / 10); which models dispersion force 
interaction arising from pi- and n-electrons of the solute (also called E)  
Vx Abraham descriptor – McGowan molar volume (L·mol
-1 / 100) of the solute  
IA, IB, IAB, IN  indicator indices: unit value, indicating that a molecule is an acid, base, ampholyte, or neutral, 
respectively, and zero otherwise 
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Appendix. Function Minimized in Refinement of Cocrystal Solubility Products and Drug-Surfactant Binding 
Constants 
Function Minimized in the Weighted Nonlinear Regression Analysis 
The refined equilibrium constants (drug-micelle binding constant, Kn, cocrystal Ksp and API intrinsic 
solubility, S0), along with other unrefined constants (e.g., API and coformer pKa values), and the given 
independent variables (sample weights, reagent volumes, surfactant concentration, etc.), are used to calculate 
the dependent variables: the eutectic/eutectoid total concentrations of the API (general symbol Xtot) and the 
coformer (general symbol Ytot). The calculated total concentrations are then compared to the corresponding 
observed values at each measured pH. The refined ‘best’ values are those which produce a minimum in the 





















































  (A.1) 
N0 and N0
cof 
are the number of API and coformer measurements as a function of pH, respectively; σ is the 
estimated standard deviation in the measured log value. (When σ values were not available, 0.1 log unit was 
assumed.) Xtot
calc and Ytot
calc are functions of the equilibrium constants, as well as the independent variables.  
Overview of the refinement procedure 
Two separate stages of refinement comprise the overall procedure.  
(i) At the ‘local’ refinement stage (pp. 152-154 [27]), the mass balance equations (e.g., Eqs. (8)-(10)), 
which are nonlinear polynomials in terms of the reactant concentrations and equilibrium constants, 
are simultaneously solved by the Jacobian method for reactant concentrations at each measured 
solubility point, for a given set of equilibrium constants. If there are three independent reactants, then 
there will be three mass balance equations. The local step involves the inversion of a symmetric 
Jacobian matrix (whose elements are partial derivatives of total concentrations as a function of the 
logarithmic reactant concentrations) at each observed eutectic/eutectoid-pH measurement. If solids 
are part of the system, then the computation of the reactant concentrations becomes quite 
complicated, as described in detail elsewhere [16]. 
(ii) At the ‘global’ stage of refinement (pp. 154-155 [27]), the Gauss-Newton method is used to 
approximate the log Ctot values (based on the mass balance equations) by ‘normal equations’ (one for 
each sampled log Ctot-pH), linearized by Taylor series expansion. The least-squares symmetric matrix 
(of dimension equal to the number of refined parameters) to be inverted will have its elements 
computed from the first derivatives of log Ctot
calc with respect to the adjustable parameters (related to 
the ‘local’ inverse Jacobian matrix). The partial derivatives are computed at the ‘local’ refinement 
steps and elements of the global design matrix are accumulated for each pH point. When all the data 
points have been processed, the accumulated matrix is inverted and the newly-estimated equilibrium 
constants are incrementally calculated. The iterative process continues until the improvements are 
vanishingly small. 
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Weighting scheme and goodness-of-fit, GOF 











where Nv is the number of varied equilibrium constants. GOF values of 1 are ideal. It would mean that on 
the average, the calculated and observed log Ctot - pH curves are about one standard deviation (0.05-0.1 log 
unit) apart. GOF 0.5-1.5 is often obtained for successful refinement. GOF >> 2 indicates that log Ctot 
measurements are of poor quality, or the experimental standard deviations are underestimated, or the 
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